In the absence of a submission from the holder of the marketing authorisation, eltrombopag (Revolade®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with acquired severe aplastic anaemia who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haemoatopoietic stem cell transplantation.